Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiora Pharmaceuticals

2.86
+0.04001.42%
Post-market: 2.860.00000.00%19:22 EDT
Volume:15.90K
Turnover:45.43K
Market Cap:8.71M
PE:-1.00
High:2.94
Open:2.80
Low:2.80
Close:2.82
Loading ...

Kiora Pharmaceuticals Inc. Concluded Annual Stockholders Meeting

Reuters
·
05 Jun

Kiora Pharmaceuticals: Strategic Partnerships and Promising Financial Prospects Drive Buy Rating

TIPRANKS
·
05 Jun

Top Midday Gainers

MT Newswires Live
·
04 Jun

BRIEF-Kiora Pharmaceuticals - Enters Exclusive Option Agreement With Senju - SEC Filing

Reuters
·
03 Jun

Kiora Pharmaceuticals Inc - Total Deal Value About $110 Mln Plus Royalties

THOMSON REUTERS
·
03 Jun

Kiora Pharmaceuticals Inc - Senju to Pay Kiora $1.25 Mln Immediate Option Payment - SEC Filing

THOMSON REUTERS
·
03 Jun

Kiora Pharmaceuticals Grants Senju Exclusive Option for KIO-301 Ophthalmic Treatment in Asia

Reuters
·
03 Jun

Kiora Pharmaceuticals Reports Q1 2025 Financial Results

TIPRANKS
·
31 May

Kiora Pharmaceuticals: Strong Financial Position and Strategic Partnerships Propel Buy Rating

TIPRANKS
·
11 May

Kiora Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a share - Earnings Preview

Reuters
·
06 May

Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy

Newsfile
·
05 May

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Newsfile
·
04 Apr

Kiora Pharmaceuticals Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

Kiora Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Mar

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Newsfile
·
25 Mar

Kiora Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview

Reuters
·
21 Mar

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Newsfile
·
13 Feb

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Newsfile
·
11 Feb